Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study

Compared with TACE plus lenvatinib, triple therapy with TACE, lenvatinib, and PD-1 inhibitor resulted in better PFS and OS. These findings support the consideration of this triple combination as a promising first-line treatment option for unresectable huge HCC and warrant further validation in prospective studies.